215 related articles for article (PubMed ID: 34746992)
1. A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA.
Campbell NL; Hines L; Epstein AJ; Walker D; Lockefeer A; Shiozawa A
Drugs Aging; 2021 Dec; 38(12):1075-1085. PubMed ID: 34746992
[TBL] [Abstract][Full Text] [Related]
2. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder.
Chatterjee S; Walker D; Kimura T; Aparasu RR
Drugs Aging; 2021 Apr; 38(4):311-326. PubMed ID: 33682017
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of providers who prescribed only anticholinergic medications for overactive bladder in 2020.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Am J Obstet Gynecol; 2023 Sep; 229(3):316.e1-316.e7. PubMed ID: 37244459
[TBL] [Abstract][Full Text] [Related]
5. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
6. Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder.
Shiota T; Torimoto K; Okuda M; Iwata R; Kumamoto H; Miyake M; Hirayama A; Tanaka N; Fujimoto K
Low Urin Tract Symptoms; 2020 Jan; 12(1):54-61. PubMed ID: 31460706
[TBL] [Abstract][Full Text] [Related]
7. The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder.
Suehs BT; Caplan EO; Hayden J; Ng DB; Gaddy RR
Drugs Aging; 2019 Oct; 36(10):957-967. PubMed ID: 31359329
[TBL] [Abstract][Full Text] [Related]
8. Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States.
Cooperberg MR; Mbassa R; Walker D; Meeks W; Lockefeer A; Jiang B; Li T; Johnston K; Fang R
Ther Adv Urol; 2023; 15():17562872221150572. PubMed ID: 36703880
[TBL] [Abstract][Full Text] [Related]
9. Anticholinergic Prescribing in Medicare Part D Beneficiaries Residing in Nursing Homes: Results from a Retrospective Cross-Sectional Analysis of Medicare Data.
Niznik J; Zhao X; Jiang T; Hanlon JT; Aspinall SL; Thorpe J; Thorpe C
Drugs Aging; 2017 Dec; 34(12):925-939. PubMed ID: 29214512
[TBL] [Abstract][Full Text] [Related]
10. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
[TBL] [Abstract][Full Text] [Related]
11. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients.
Yoshida M; Kato D; Nishimura T; Van Schyndle J; Uno S; Kimura T
Int J Urol; 2018 Oct; 25(10):855-862. PubMed ID: 30069973
[TBL] [Abstract][Full Text] [Related]
12. Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study.
Just KS; Schultze KA; Dormann H; Seufferlein T; Gräff I; Scholl C; Schwab M; Stingl JC
Eur J Clin Pharmacol; 2023 Sep; 79(9):1185-1193. PubMed ID: 37382655
[TBL] [Abstract][Full Text] [Related]
13. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
Rai BP; Cody JD; Alhasso A; Stewart L
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
[TBL] [Abstract][Full Text] [Related]
14. Overactive bladder medication prescription trends from 2014 to 2018.
Sripad A; Raker C; Shireman T; Sung V
Neurourol Urodyn; 2022 Mar; 41(3):806-812. PubMed ID: 35132687
[TBL] [Abstract][Full Text] [Related]
15. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
16. Are anticholinergic medications used for overactive bladder associated with new onset depression? A population-based matched cohort study.
Welk B; McArthur E
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1710-1714. PubMed ID: 33015899
[TBL] [Abstract][Full Text] [Related]
17. Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder.
Jaggi A; Nazir J; Fatoye F; Quelen C; Tu X; Ali M; Siddiqui E; Covernton PJO; Landeira M; Choudhury N
Drugs Aging; 2021 Oct; 38(10):911-920. PubMed ID: 34386936
[TBL] [Abstract][Full Text] [Related]
18. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
19. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
[TBL] [Abstract][Full Text] [Related]
20. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
